March 12, 2012
The National Institute for Health and Clinical Excellence (NICE) on Friday recommended Merck & Co.'s new hepatitis C drug Victrelis (boceprevir) for use in Britain's state health service. Although it often shuns expensive new treatments on cost grounds, NICE noted that the significant improvements seen with Victrelis make it a cost-effective option. Victrelis costs £30,800 (US $48,109) for a 44-week regimen; it is designed to be administered with peginterferon-alfa and ribavirin, which add £11,000 (US $17,178) to the total. The draft guidelines are open for consultation before final approval.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Long-Acting HIV Treatment: 5 Myths and Realities|
|Frame PrEP as Part of a 'Healthy Sex Life' for Better Adherence|
|Bictegravir in the Body -- Preliminary Information About Drug Interactions|
|A New Nuke in the Works -- GS-9131|
|Running a PrEP Clinic in a Community Pharmacy Setting|
|Incidence of All Cancers but Lung Cancer Drops After HIV Group Stops Smoking|